FBXO34 Protein Localization for Thyroid Carcinoma Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for thyroid carcinoma, such as FNAB, face challenges in accurately distinguishing benign from malignant thyroid nodules, particularly in indeterminate cases, leading to unnecessary surgeries due to unsatisfactory accuracy.
Innovation Solution
The use of FBXO34 protein as a diagnostic marker, detected through its unique subcellular localization in thyroid cells, where it appears in both the cytoplasm and nucleus of malignant cells but only in the nucleus of benign cells, facilitating the differentiation between benign and malignant thyroid lesions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods (FNAB, cytological examination) are used to distinguish benign from malignant thyroid nodules, then the diagnostic process is simple and widely available, but the accuracy is unsatisfactory leading to misdiagnosis of indeterminate cases
Solution Approach 1:
The invention applies local quality by examining the specific subcellular localization of FBXO34 protein within thyroid cells. Instead of analyzing overall protein presence, the method focuses on the precise spatial distribution pattern (nuclear vs. cytoplasmic) to differentiate malignant from benign lesions, thereby improving diagnostic accuracy through localized analysis of a specific cellular compartment
Solution Approach 2:
The invention changes the diagnostic parameter from general cytological features to the specific subcellular localization pattern of FBXO34 protein. By detecting whether FBXO34 is localized in the nucleus, cytoplasm, or both, the method transforms the diagnostic approach into a more precise measurement that can reliably distinguish indeterminate cases
2Reliability
If FNAB is used as the primary diagnostic tool, then the procedure is minimally invasive and cost-effective, but it produces indeterminate results in 15-30% of cases requiring further surgery
Solution Approach 1:
The invention performs preliminary action by analyzing the subcellular localization of FBXO34 protein during the initial FNAB procedure. This additional analysis is conducted on the same cytological sample before surgical intervention is planned, allowing for more reliable differentiation of indeterminate cases and preventing unnecessary surgeries without requiring separate procedures or delaying diagnosis
3Measurement precision
If more aggressive diagnostic approaches are adopted to improve accuracy, then diagnostic precision increases, but patient burden and procedural complexity increase
Solution Approach 1:
The invention applies universality by making the FBXO34 localization analysis applicable to all thyroid nodule cases, including benign, indeterminate, and malignant lesions. The same immunohistochemical staining and localization analysis method works universally across different lesion types, providing a single streamlined approach that maintains simplicity while improving accuracy for all patients
Data Source
Figure 1A~1P
Figure 2
Figure 3
AI summary
The present invention concerns a method for in vitro diagnosis of thyroid carcinoma by detecting the localization of FBXO34 protein.